Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deferred Tax LiabilityOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Avalo Therapeutics (AVTX) Current Assets (2016 - 2025)

Avalo Therapeutics (AVTX) has disclosed Current Assets for 12 consecutive years, with $113.8 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Current Assets rose 32.15% year-over-year to $113.8 million, compared with a TTM value of $113.8 million through Sep 2025, up 32.15%, and an annual FY2024 reading of $138.9 million, up 1554.44% over the prior year.
  • Current Assets was $113.8 million for Q3 2025 at Avalo Therapeutics, down from $115.2 million in the prior quarter.
  • Across five years, Current Assets topped out at $138.9 million in Q4 2024 and bottomed at $7.5 million in Q2 2023.
  • Average Current Assets over 5 years is $61.2 million, with a median of $47.4 million recorded in 2021.
  • The sharpest move saw Current Assets tumbled 74.74% in 2022, then surged 1554.44% in 2024.
  • Year by year, Current Assets stood at $61.8 million in 2021, then crashed by 73.46% to $16.4 million in 2022, then plummeted by 48.86% to $8.4 million in 2023, then soared by 1554.44% to $138.9 million in 2024, then decreased by 18.03% to $113.8 million in 2025.
  • Business Quant data shows Current Assets for AVTX at $113.8 million in Q3 2025, $115.2 million in Q2 2025, and $126.9 million in Q1 2025.